

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

07 April 2022 (07.04.2022)



(10) International Publication Number

WO 2022/069894 A1

(51) International Patent Classification:

C07D 285/08 (2006.01) A61P 3/10 (2006.01)
C07F 9/09 (2006.01) A61K 31/433 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/GB2021/052535

(22) International Filing Date:

30 September 2021 (30.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2015585.9 01 October 2020 (01.10.2020) GB

(71) Applicant: **BETAGENON BIO AB** [SE/SE]; Västra Strandgatan 9B, 90326 Umeå (SE).

(71) Applicant (for UZ only): **CARLING, David Andrew** [GB/GB]; The Belgrave Centre, Talbot Street, Nottingham Nottinghamshire NG1 5GG (GB).

(72) Inventors: **EDLUND, Thomas**; Kungsgatan 46B, 90326 Umeå (SE). **WESTMAN, Jacob**; Jonsund Blomsberg 109, 74497 Järlåsa (SE).

(74) Agent: **CARLING, David Andrew**; Potter Clarkson, The Belgrave Centre, Talbot Street, Nottingham Nottinghamshire NG1 5GG (GB).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: THIADIAZOLONE DERIVATIVES AND THEIR USE AS AMPK AGONISTS FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS



(57) Abstract: The invention relates to a compound of formula I, wherein: R¹ is as defined in the specification, or a pharmaceutically acceptable salt or solvate thereof, which compounds are useful in the treatment of a disorder or condition ameliorated by the activation of AMPK, particularly as prodrugs.



WO 2022/069894 A1

Field of the Invention

5 The present invention relates to novel compounds, and the use of such compounds in medicine. In particular, the present invention relates to compounds that are useful in treating a disorder or condition ameliorated by the activation of AMP-activated protein kinase.

10 Background of the Invention

AMP-activated protein kinase (AMPK) is a protein kinase enzyme that consists of three protein sub-units and is activated by hormones, cytokines, exercise, and stresses that diminish cellular energy state (e.g. glucose deprivation). Activation of AMPK increases
15 processes that generate adenosine 5'-triphosphate (ATP) (e.g., fatty-acid oxidation) and restrains others such as fatty acid-, glycerolipid- and protein-synthesis that consume ATP, but are not acutely necessary for survival. Conversely, when cells are presented with a sustained excess of glucose, AMPK activity diminishes and fatty acid-, glycerolipid- and protein-synthesis are enhanced. AMPK thus is a protein kinase
20 enzyme that plays an important role in cellular energy homeostasis. Therefore, the activation of AMPK is coupled to glucose lowering effects and triggers several other biological effects, including the inhibition of cholesterol synthesis, lipogenesis, triglyceride synthesis, and the reduction of hyperinsulinemia.

25 Given the above, AMPK is a preferred target for the treatment of the metabolic syndrome and especially type 2 diabetes. AMPK is also involved in a number of pathways that are important for many different diseases (e.g. AMPK is also involved in a number of pathways that are important in CNS disorders, fibrosis, osteoporosis, heart failure and sexual dysfunction).


30

AMPK is also involved in a number of pathways that are important in cancer. Several tumour suppressors are part of the AMPK pathway. AMPK acts as a negative regulator of the mammalian TOR (mTOR) and EF2 pathway, which are key regulators of cell growth and proliferation. The deregulation may therefore be linked to diseases such
35 as cancer (as well as diabetes). AMPK activators may therefore be of utility as anti-cancer drugs.

It has been shown that AMPK activator drugs (e.g. metformin and 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide (i.e. the compound of formula II below)) are effective at treating pain. Das and co-workers report that, following lumbar disc puncture, postinjury treatment in mice with AMPK activator drugs reduces mechanical hypersensitivity (Das V, *et al.* Reg Anesth Pain Med 2019;0:1–5. doi:10.1136/rapm-2019-100839). Similarly, Das and co-workers also report that early treatment with AMPK activator drugs reduces mechanical hypersensitivity in a postoperative pain model in mice (Das V, *et al.* Reg Anesth Pain Med 2019;0:1–6. doi:10.1136/rapm-2019-100651). These drugs also normalize the AMPK pathway in the dorsal root ganglion. AMPK activators may therefore be used in the treatment of pain, particularly post-operative pain.

It has also been shown that hepatic steatosis may be regulated by AMPK (Zhao *et al.* J. Biol. Chem. 2020 295: 12279- 12289). Activation of AMPK inhibits *de novo* lipogenesis while promoting fatty acid oxidation (β -oxidation) in the liver. AMPK activation also reduces free fatty acid release from adipose tissue and prevents hepatic steatosis. Pharmacological activation of AMPK in the liver was reported to promote beneficial effects on multiple aspects of non-alcoholic fatty liver disease (NAFLD). For example, activation of AMPK was found to improve non-alcoholic steatohepatitis (NASH) in both murine and simian animal models. Accordingly, AMPK activators may be useful in the treatment of NAFLD and NASH.

An example of an AMPK activator is 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide (i.e. the compound of formula II), which was first disclosed in WO 2011/004162.




As an AMPK agonist (i.e. an AMPK activator), the compound of formula II is useful in the treatment of disorders or conditions which are ameliorated by the activation of AMPK. Such compounds may be useful in the treatment of cardiovascular disease (such as heart failure), diabetic kidney disease, type 2 diabetes, insulin resistance, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, pain, opioid addiction, obesity, cancer, inflammation (including chronic inflammatory diseases), autoimmune diseases, osteoporosis and intestinal diseases.

Although a number of AMPK activators are known, there is still a need for the development of novel compounds for the treatment of a disorder or condition ameliorated by the activation of AMPK. The inventors have now found novel compounds that are metabolised *in vivo* to form a known AMPK activator, with a surprising enhancement of the bioavailability of the AMPK activator. Said compounds were also found to activate AMPK.

The listing or discussion of an apparently prior-published document in this specification should not necessarily be taken as an acknowledgement that the document is part of the state of the art or is common general knowledge.

Detailed Description of the Invention

In a first aspect of the invention, there is provided a compound of formula I



wherein R¹ is selected from the group consisting of -C(O)-C₂H₄-CO₂H and -PO₃H₂, or a pharmaceutically acceptable salt or solvate thereof.

These compounds, including pharmaceutically acceptable salts and solvates thereof, may be referred to herein as the "compounds of the invention".

The compounds of the invention have been found to metabolise *in vivo* to form 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl] benzamide (referred to herein as a compound of formula II) which is known to be an AMPK activator. In this regard, the compounds of the invention may be considered to be prodrugs of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide.

Pharmaceutically acceptable salts include base salts. Such salts may be formed by conventional means, for example by reaction of a free acid or phosphate form of a compound of the invention with one or more equivalents of an appropriate base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. *in vacuo*, by

freeze-drying or by filtration). Salts may also be prepared using techniques known to those skilled in the art, such as by exchanging a counter-ion of a compound of the invention in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.

5

Pharmaceutically acceptable salts of potential utility include those discussed in J. Pharmaceutical Sciences, 66: 1-19 (1977), by Berge *et al.* In some embodiments, the salts can be prepared *in situ* during the final isolation and/or purification for a compound of the invention, or separately by reaction of the free acid function with a
10 suitable inorganic or organic base. Suitable counterions for said salts include, but are not limited to, metals, such as sodium, potassium and calcium, or amines, such as triethylammonium and lysine. Particular pharmaceutically acceptable addition salts that may be mentioned include alkali metal salts, alkaline earth metal salts or quaternary ammonium salts of the compound of formula I.

15

"Alkali metals" are metals found, along with hydrogen, in group I of the periodic table, most notably lithium, sodium, potassium, rubidium and caesium. It will therefore be understood that an "alkali metal salt" is a chemical compound consisting of an assembly of one or more alkali metal cations and one or more associated anions.

20

"Alkaline earth metals" are metals found in group II of the periodic table, most notably magnesium, calcium, strontium and barium. It will therefore be understood that an "alkaline earth metal salt" is a chemical compound consisting of an assembly of one or more alkaline earth metal cations and one or more associated anions.

25

"Quaternary ammonium" cations are positively charged ions of the structure $[NR_4]^+$, where each R may independently represent H, a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group or an aryl group. Alternatively, a "quaternary ammonium" cation is a cationic form (particularly a protonated form) of an amino acid, such as an amino
30 acid bearing a positively charged side chain (e.g. lysine, histidine or arginine). It will therefore be understood that a "quaternary ammonium salt" is a chemical compound consisting of an assembly of one or more quaternary ammonium cations and one or more associated anions.

35

Unless otherwise specified, alkyl groups defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of two or three, as appropriate) of carbon atoms, be branched-chain, and/or cyclic (so forming a cycloalkyl group). When there is a sufficient number (i.e. a minimum of four) of carbon atoms, such groups may also

be part cyclic (so forming a partial cycloalkyl group). For example, cycloalkyl groups that may be mentioned include cyclopropyl, cyclopentyl and cyclohexyl. Similarly, part cyclic alkyl groups (which may also be referred to as "part cycloalkyl" groups) that may be mentioned include cyclopropylmethyl.

5

Unless otherwise specified, alkenyl groups defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of three) of carbon atoms, be branched-chain. For the avoidance of doubt, particular alkenyl groups that may be mentioned include straight chain (i.e. not branched) alkenyl groups.

10

Unless otherwise specified, alkynyl groups defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of four) of carbon atoms, be branched-chain. For the avoidance of doubt, particular alkynyl groups that may be mentioned include straight chain (i.e. not branched) alkynyl groups.

15

For the avoidance of doubt, unless otherwise specified, groups referred to herein as "alkyl", "alkenyl" and/or "alkynyl" will be taken as referring to the highest degree of unsaturation in a bond present in such groups. For example, such a group having a carbon-carbon double bond, and, in the same group, a carbon-carbon triple bond will be referred to as "alkynyl".

20

As may be used herein, the term aryl may refer to aromatic groups. Such groups may be monocyclic or bicyclic and, when bicyclic, be either wholly or partly aromatic. aryl groups that may be mentioned include C₆₋₁₀ aryl groups, particularly phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, indanyl, and the like (e.g. phenyl and naphthyl). For the avoidance of doubt, the point of attachment of substituents on aryl groups may be *via* any suitable carbon atom of the ring system.


25

Accordingly, an "alkali metal salt", "alkaline earth metal salt" or "quaternary ammonium salt" of a compound of formula I refers to a compound comprising one or more alkali metal, alkaline earth metal or quaternary ammonium cations (e.g. lithium, magnesium, calcium, ammonium, tetramethylammonium and, particularly, sodium and potassium) and one or more anions of a compound of formula I.


30

Particular, alkali metal, alkaline earth metal and quaternary ammonium salts of a compound of formula I that may be mentioned include compounds of formula III,

35



and formula IV,



- 5 wherein X^+ represents an alkali metal, alkaline earth metal or quaternary ammonium (e.g. lithium, magnesium, calcium, ammonium, tetramethylammonium and, particularly, sodium and potassium) cation, with appropriate stoichiometric adjustments being made in view of charges of the ions.
- 10 The skilled person will recognize that, when dissolved in a suitable solvent (e.g. water) the pharmaceutically acceptable salt (e.g. alkali metal salt, alkaline earth metal salt or quaternary ammonium salt) of the compound of formula I may dissociate into its anionic and cationic components.
- 15 Pharmaceutically acceptable salts of the compound of formula I may be prepared in accordance with techniques that are well known to those skilled in the art. For example, the compound of formula I may be reacted with the appropriate alkali metal hydroxide, or an alternative alkali metal base compound. Salt switching techniques may also be used to convert one salt into another salt.
- 20 In particular embodiments, the pharmaceutically acceptable salt is a sodium or potassium salt of the compound of formula I. Preferably, the pharmaceutically acceptable salt is the sodium salt.
- 25 The compounds disclosed herein may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water and ethanol, and it is intended that

the invention embraces both solvated and unsolvated forms of the compounds of the invention.

5 The term "solvate" refers to a complex of variable stoichiometry formed by a solute and solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, methanol, ethanol, and acetic acid. Solvates in which water is the solvent molecule are typically referred to as hydrates. Hydrates include compositions containing stoichiometric amounts of water, as well as compositions containing variable
10 amounts of water.

Compounds of formula I contain double bonds and may thus exist as *E* (entgegen) and *Z* (zusammen) geometric isomers about each individual double bond. All such isomers and mixtures thereof are included within the scope of the invention.

15 Compounds of formula I may exist as regioisomers and may also exhibit tautomerism. All tautomeric forms and mixtures thereof are included within the scope of the invention.

20 The present invention also embraces isotopically-labelled compounds of formula I which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature (or the most abundant one found in nature). All isotopes of any particular atom or element as specified herein are
25 contemplated within the scope of the invention. Hence, the compounds of formula I also include deuterated compounds, i.e. compounds of formula I in which one or more hydrogen atoms are replaced by the hydrogen isotope deuterium.


Throughout this specification, structures may or may not be presented with chemical
30 names. Where any question arises as to nomenclature, the structure prevails. Where it is possible for the compound to exist as a tautomer (e.g. in an alternative resonance form) the depicted structure represents one of the possible tautomeric forms, wherein the actual tautomeric form(s) observed may vary depending on environmental factors such as solvent, temperature or pH. All tautomeric (and resonance) forms and
35 mixtures thereof are included within the scope of the invention.

Unless indicated otherwise, all technical and scientific terms used herein will have their common meaning as understood by one of ordinary skill in the art to which this invention pertains.

- 5 For the avoidance of doubt, the skilled person will understand that references herein to particular aspects of the invention (such as the first aspect of the invention) will include references to all embodiments and particular features thereof, which embodiments and particular features may be taken in combination to form further embodiments and features of the invention.

10


In particular embodiments, the compound of formula I is Compound 3:



Compound 3,

- or a pharmaceutically acceptable salt or solvate thereof. Compound 3 is known as 4-
 15 ({(5Z)-5-[(4-chlorobenzoyl)imino]-2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-4-yl}methoxy)-4-oxobutanoic acid. In a further embodiment, the compound of the invention is a sodium salt of Compound 3.

In other embodiments, the compound of formula I is Compound 5A:




20

Compound 5A,

- or a pharmaceutically acceptable salt or solvate thereof. Compound 5A is known as
 {(5Z)-5-[(4-chlorobenzoyl)imino]-2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-4-yl}methyl phosphoric acid. In a further embodiment, the compound
 25 of the invention is a sodium salt of Compound 5A, particularly disodium {(5Z)-5-[(4-chlorobenzoyl)imino]-2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-4-yl}methyl phosphate (referred to herein as "Compound 5").

The compounds of the invention may be considered to be prodrugs of 4-chloro-N-[2-
[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide as they have been
found to break down *in vivo* to form said compound. 4-Chloro-N-[2-[(4-
chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide maybe depicted as the
5 compound of formula II



The term "prodrug" refers to a compound that, following oral or parenteral
10 administration, is metabolised *in vivo* to yield a pharmalogically active compound in
an experimentally-detectable amount, and within a predetermined time (e.g. within a
dosing interval of between 6 and 24 hours (i.e. once to four times daily)). For
theavoidance of doubt, the term "parenteral" administration includes all forms of
administration other than oral administration. General information on prodrugs may
15 be found e.g. in Bundegaard, H. "Design of Prodrugs" p. 1-92, Elsevier, New York-
Oxford (1985).

It has been found that administration of the compounds of the invention surprisingly
resulted in a significant increase in the bioavailability and systemic exposure of 4-
20 chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide as
compared to the bioavailability and systemic exposure observed following
administration of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-
yl]benzamide.

25 The bioavailability of a drug is the amount of an administered dose that reaches the
systemic circulation in that drug form. Sufficient bioavailability is important to achieve
a therapeutically active concentration at the site of action. An improvement (i.e. an
increase) in bioavailability may be demonstrated by measuring the C_{max} or the area
under the curve (AUC) in the blood of a subject following administration of the
30 compound (or pharmaceutical formulation thereof) to that subject. The compounds
and formulations of the invention are useful in the therapies described herein in a
subject in need of such therapy. Subjects that may be mentioned include animals,
such as mammals. Particular mammals that might be mentioned include, for example,
primates (e.g., humans, male or female), cows, horses, dogs and cats. Preferably the
35 subject is a human.

The terms "C_{max}" and "AUC" will be well understood by the person skilled in the art to refer, in the present context, to the peak plasma concentration of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide after administration (e.g. to a human subject) and the integral of the concentration/time curve for that substance following the administration of the compound of the invention (or formulation thereof), respectively.

It has been found that administration of a compound of the invention resulted in a particularly enhanced bioavailability of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide *in vivo*, as is evidenced by the data in the examples. These data show that plasma exposure of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide is increased when said compound is administered to a mammalian subject as compared to the plasma exposure observed following administration of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide.

Thus, administration of the compounds of the invention is capable of increasing the bioavailability of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide compared to administration of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide. In this context, the phrase "increasing the bioavailability" means that administration of the compound of the invention results in a larger systemically available fraction of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide *in vivo* compared to administration of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide. The increase in the systemically available fraction of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide may be at least about 10%, (at least) about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100% (i.e. 2-fold), about 150%, about 200% (i.e. 3-fold), about 250%, about 300% (i.e. 4-fold), about 350%, or about 400% (i.e. 5-fold).

The improvement of the bioavailability provided by the compounds of the invention may be demonstrated using suitable methods known in the art. For example, the improvement in bioavailability may be demonstrated by comparing the pharmacokinetic data (e.g. AUC data) for a subject who has been administered a compound of the invention with the corresponding data for a subject who has been administered 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide.

As indicated by the examples, the compounds of the invention have comparable stability to 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide in mildly basic solutions (e.g. at pH 7.4). Thus, the compounds of the invention are suited to being prepared into pharmaceutical formulations for administration to patients. However, both the compounds of the invention and Compound of Formula II show reduced stability under acidic condition so decomposition in the stomach environment is likely unless adequate protection is provided for orally administered formulations.

The compounds of the invention have also been found to be surprisingly effective at activating AMPK, as is evidenced by the data in the examples. As AMPK activators (i.e. AMPK agonists), the compounds of the invention may be useful in the treatment of disorders or conditions which are ameliorated by the activation of AMPK. Such compounds may therefore be useful in the treatment of the particular diseases described herein.


The compounds of the invention may be prepared from 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide. 4-Chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide may, in turn, be prepared in accordance with techniques that are well known to those skilled in the art. For example, 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide may be made in accordance with the techniques described in international patent application WO 2011/004162, and all of its content is hereby incorporated by reference.

Compounds of the invention as described herein may be prepared in accordance with techniques that are well known to those skilled in the art, such as those described in the examples provided hereinafter.

Compounds of formula I may be obtained by analogy with the processes known in the literature, or by conventional synthetic procedures, in accordance with standard techniques, from available starting materials using appropriate reagents and reaction conditions. In this respect, the skilled person may refer to *inter alia* "Comprehensive Organic Synthesis" by B. M. Trost and I. Fleming, Pergamon Press, 1991.

For example, there is provided a process for the preparation of a compound of the invention as hereinbefore defined, which process comprises:


(i) reaction of a compound of formula V,



5 with a suitable acid or acid anhydride (e.g. succinic anhydride) in the presence of a suitable base (e.g. 4-dimethylaminopyridine) and a suitable solvent (e.g. tetrahydrofuran) according to procedures known to the person skilled in the art; or


(ii) reaction of a compound of formula VI,

10



15 with a suitable acid or suitable acid salt (e.g. phosphoric acid, optionally presented as an ammonium dihydrogen phosphate) in the presence of a suitable base (e.g. 4-tributylamine) and a suitable solvent (e.g. dichloromethane) according to procedures known to the person skilled in the art.

20 The compound of formula V may be obtained by conventional synthetic procedures, in accordance with standard techniques, from available starting materials using appropriate reagents and reaction conditions. For example, the compound of formula V may be prepared by reaction of a compound of formula II,



25 with formaldehyde in the presence of a suitable base (e.g. triethylamine) and a suitable solvent (e.g. *N,N*-dimethylformamide) according to procedures known to the person skilled in the art.

30 Similarly, the compound of formula VI may also be obtained by conventional synthetic procedures, in accordance with standard techniques, from available starting materials using appropriate reagents and reaction conditions. For example, the compound of

formula VI may be prepared by reaction of a compound of formula V with a chlorinating agent (e.g. thionyl chloride) according to procedures known to the person skilled in the art.

5 Likewise, the compound of formula II (i.e. 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide; referred to in the examples as Compound 1) may be prepared in accordance with techniques that are well known to those skilled in the art, e.g. the techniques described in international patent application no. WO 2011/004162.

10

Compounds of the invention may be isolated from their reaction mixtures and, if necessary, purified using conventional techniques as known to those skilled in the art. Thus, processes for preparation of compounds of the invention as described herein may include, as a final step, isolation and optionally purification of the compound of

15 the invention.

Pharmaceutical Formulations

20

As indicated herein, the compounds of the invention are useful as therapeutic agents for treating a variety of medical disorders or conditions. Typically, compounds of the invention will be administered to a subject in need thereof in the form of a pharmaceutical formulation.

25

According to a second aspect of the invention, there is provided a pharmaceutical formulation comprising the compound of formula I (or a pharmaceutically acceptable salt or solvate thereof). Such formulations are referred to herein as the formulations of the invention. All embodiments and particular features thereof described herein in respect of the first aspect of the invention are disclosed herein in respect of the second aspect of the invention.

30

The pharmaceutical formulations of the second aspect of the invention may be prepared in accordance with standard and/or accepted pharmaceutical practice.

35

In an embodiment of the second aspect of the invention, the compound of the invention (or the pharmaceutically acceptable salt or solvate thereof) is the sole active pharmaceutical ingredient present in the formulation. In a further embodiment of the second aspect of the invention, the compound of the invention (or a pharmaceutically acceptable salt or solvate thereof) is present in the formulation alongside one or more

other active pharmaceutical ingredients, or may be administered as part of a combination therapy with one or more other active pharmaceutical ingredients.

The formulations of the second aspect of the invention will generally be provided as a mixture comprising the compound of the invention (or a pharmaceutically acceptable salt or solvate thereof) and one or more pharmaceutically acceptable excipients. The one or more pharmaceutically acceptable excipients may be selected with due regard to the intended route of administration in accordance with standard pharmaceutical practice. Such pharmaceutically acceptable excipients are preferably chemically inert to the active compound and preferably have no detrimental side effects or toxicity under the conditions of use. Suitable pharmaceutical formulations may be found in, for example, Remington The Science and Practice of Pharmacy, 19th ed., Mack Printing Company, Easton, Pennsylvania (1995). A brief review of methods of drug delivery may also be found in e.g. Langer, Science 249, 1527 (1990).

It has been found that pH modifying excipients are particularly advantageous in the formulations of the invention. pH modifying excipients are those which substantially alter the pH of an aqueous solution of a formulation compared to the pH of an aqueous solution of the same formulation that does not otherwise comprise said excipients. A pH modifying excipient may raise (or lower) the pH of an aqueous solution of a formulation (e.g. to a pH of 8 or more) compared to an aqueous solution of the same formulation that does not comprise said excipient. Such excipients may be useful for increasing (i.e. improving) the aqueous solubility and/or stability of the compound of the invention in the formulation.

In the formulations of the invention, it has been found that basic excipients are useful in combination with the compounds of the inventions, particularly with Compound 5 and other salts thereof, and result in an improvement in the solubility of the compound. Thus, in particular embodiments of the second aspect of the invention, the at least one pharmaceutically acceptable excipient is a basic excipient.

As used herein, the term "basic excipient" refers to a pharmaceutically acceptable excipient that increases the microenvironmental pH of the formulation. Modulation of the microenvironmental pH of a formulation has been found to improve the dissolution of the active ingredient in the formulation, which in turn may lead to enhanced oral absorption of the active ingredient. Particular basic excipients that may be mentioned include magnesium oxide, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, magnesium carbonate and

calcium carbonate. In particular embodiments, the basic excipient is magnesium oxide.

Other pharmaceutically acceptable excipients may also be present in the formulation of the invention (either in addition to said basic excipient or in the absence of such an excipient). For example, formulations of the invention may contain a lubricant, a binder, a filler, a surfactant, a diluent, an anti-adherent, a coating, a flavouring, a colourant, a glidant, a preservative, a sweetener, a disintegrant, an adsorbent, a buffering agent, an antioxidant, a chelating agent, a dissolution enhancer, a dissolution retardant and/or a wetting agent.

Particular pharmaceutically acceptable excipients that may be mentioned include microcrystalline cellulose, lactose monohydrate, crospovidone, magnesium stearate, colloidal silicon dioxide, anhydrous lactose, dicalcium phosphate, mannitol, pregelatinised starch, hydroxypropyl cellulose, povidone, low-substituted hydroxypropyl cellulose, croscarmellose sodium, sodium starch glycolate, sodium stearyl fumarate, talc, hydroxypropyl methylcellulose, polysorbate 80, sodium lauryl sulphate, poloxamer 188, poloxamer 407, propylene glycol, titanium dioxide, hypromellose phthalate, hypromellose acetate succinate, methacrylic acid, methyl methacrylate copolymer, Opadry® I, Opadry® II.

In the preparation of a pharmaceutical formulation of the compounds of the invention for oral administration, the compounds of the invention may be mixed, either together or separately, with one or more of the pharmaceutical excipients (including basic excipients) listed above.

Mixtures of a compound of the invention and one or more pharmaceutically acceptable excipients may be processed into pellets or granules, or compressed into tablets. Thus, pharmaceutical formulations of the invention include formulations that are provided in the form of a tablet, mini-tablets, blocks, pellets, particles, granules or a powder for oral administration. Mixtures of a compound of the invention and one or more pharmaceutically acceptable excipients may also be provided in a form that is suitable for subcutaneous or intramuscular delivery, such as an injectable solution or a freeze-dried powder suitable for reconstitution in a suitable fluid prior to administration.

The skilled person will understand that formulations described herein may act systemically, and may therefore be administered accordingly using suitable techniques known to those skilled in the art. Formulations as described herein will normally be

administered orally, subcutaneously or intramuscularly in a suitable pharmaceutically acceptable dosage form. The pharmaceutical formulation of the second aspect of the invention is preferably an oral pharmaceutical formulation.

5 Formulations of the invention may be prepared for oral administration in the form of a capsule. For example, capsules such as soft gelatin capsules may be prepared containing the compound of the invention alone (or a pharmaceutically acceptable salt or solvate thereof), optionally together with a suitable vehicle, e.g. vegetable oil, fat etc. Similarly, hard gelatin capsules may contain the compound of the invention alone
10 (or a pharmaceutically acceptable salt or solvate thereof) alone, or in combination with solid powdered ingredients such as a disaccharide (e.g. lactose or saccharose), an alcohol sugar (e.g. sorbitol or mannitol), a vegetable starch (e.g. potato starch or corn starch), a polysaccharide (e.g. amylopectin or cellulose derivatives) or gelling agent (e.g. gelatin).

15 Particular pharmaceutical formulations of the invention include formulations that may be mentioned are those provided in the form of a capsule or a tablet, e.g. for oral administration.

20 Preparations intended for oral administration may further comprise an enteric coating in order to prevent or minimise dissolution or disintegration in the gastric environment. As such, oral preparations (e.g. capsules or tablets) coated with an enteric coating may provide targeted release of the compound of the invention (or a pharmaceutically acceptable salt or solvate thereof) alone in the small intestine. For example, the enteric
25 coating may be present on the surface of the formulation (e.g. on the surface of a tablet or a capsule). Thus, in particular embodiments, the formulation further comprises an enteric coating.

It may be desirable to minimise dissolution or disintegration of a capsule or a tablet
30 (and the like) in the gastric environment and/or provide targeted release of the active ingredient in the small intestine. Thus, in particular embodiments, the enteric coating is present on said capsule or tablet. For example, said coating may be provided as an outer layer on said capsule or tablet.

35 The term "enteric coating" refers to a substance (e.g. a polymer) that is incorporated into an oral medication (e.g. applied onto the surface of a tablet or a capsule) and that inhibits dissolution or disintegration of the medication in the gastric environment. Enteric coatings are typically stable at the highly acidic pH found in the stomach, but

break down rapidly in higher pH of the small intestine. Therefore, enteric coatings prevent release of the active ingredient in the medication until it reaches the small intestine.

- 5 Any enteric coating known to the skilled person may be used in the present invention. Particular enteric coating materials that may be mentioned include those which comprise a substance selected from the group consisting of beeswax, shellac, an alkylcellulose polymer resin (e.g. ethylcellulose polymers, carboxymethylethylcellulose, or hydroxypropyl methylcellulose phthalate) or an acrylic
- 10 polymer resin (e.g. acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, methacrylate copolymers, aminoalkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamide copolymer, poly(methyl methacrylate), poly(methacrylic acid anhydride), methyl methacrylate, polymethacrylate, poly(methyl
- 15 methacrylate), poly(methyl methacrylate) copolymer, polyacrylamide, aminoalkyl methacrylate copolymer, poly(methacrylic acid anhydride), glycidyl methacrylate copolymers), cellulose acetate phthalate, and polyvinyl acetate phthalate. A particular polyacrylic resin that may be mentioned is polyacrylic resin HB-50.
- 20 Pharmaceutical formulations that may be mentioned include those in which the compound of the invention (or a pharmaceutically acceptable salt or solvate thereof) is present in a total amount that is at least 1% (or at least 10%, at least 30% or at least 50%) by weight of the formulation and up to 99% by weight of the formulation. The weight ratio of the compound of the invention (or a pharmaceutically acceptable
- 25 salt or solvate thereof) to the totality of the components (i.e. the compound of the invention and all pharmaceutical excipients, e.g. adjuvants, diluents and carriers) of the pharmaceutical formulation is at least 1:99 (or at least 10:90, at least 30:70 or at least 50:50) and up to 99:1.
- 30 A "therapeutically effective amount", an "effective amount" and a "dosage" as used herein refer to an amount of a compound of the invention (or a pharmaceutically acceptable salt or solvate thereof) that is sufficient to produce a desired clinical effect, which can be a therapeutic and/or beneficial effect. The effective amount or dosage will vary with the age or general condition of the subject (e.g. a human), the severity
- 35 of the condition being treated, the particular agents administered, the duration of the treatment, the nature of any concurrent treatment, the pharmaceutically acceptable excipients used, and like factors within the knowledge and expertise of those skilled in the art. As appropriate, a "therapeutically effective amount", "effective amount" or

"dosage" in any individual case can be determined by one of skill in the art by reference to the pertinent texts and literature and/or by using routine experimentation. Those skilled in the art will appreciate that the therapeutic effects need not be complete or curative, as long as some benefit is provided to the subject.

5

The skilled person will understand that compounds of the invention, and formulations thereof, may be administered (for example, by way of one or more preparations as described herein) at varying doses, with suitable doses being readily determined by one of skill in the art. The total dosage of the compound of the invention (or a pharmaceutically acceptable salt or solvate thereof) that is to be administered to a subject in need thereof may range from about 0.01 milligrams per day (mg/day) to about 3000 mg/day, about 0.1 mg/day to about 2000 mg/day, or about 1 mg/day to about 1000 mg/day (e.g. from about 10 mg/day to about 500 mg/day). Such dosages may be, for example, oral dosages of the formulations of the second aspect of the invention. When the compound of the invention (or a pharmaceutically acceptable salt or solvate thereof) is to be administered either intramuscularly or subcutaneously, the skilled person will recognise that the dosage should be adjusted accordingly.

10

15

20

25

When administered orally, treatment with such formulations may comprise administration of a unit dose formulation containing from about 0.01 mg to about 3000 mg of the compound of the invention, for example from about 0.1 mg to about 2000 mg, or from about 1 mg to about 1000 mg (e.g. from about 10 mg to about 500 mg), of the compound of the invention. Advantageously, treatment may comprise administration of the compound of the invention (e.g. in the form of one or more capsules containing said formulation) using a single daily dose. Alternatively, the total daily dosage of the compound of the invention may be administered in divided doses two, three or four times daily (e.g. twice daily with reference to the doses described herein, such as a dose of 100 mg, 250 mg, 500 mg or 1000 mg twice daily). The skilled physician will recognise that the dosage will vary from subject to subject.

30

In particular embodiments, the daily dose of the compound of the invention administered to a subject is in the range of from about 1 to about 3000 mg, preferably from about 1 to about 1000 mg.

35

The term "about" as used herein when referring to a measurable value such as an amount of a compound, dose, time, temperature, and the like, refers to variations of 20%, 10%, 5%, 1%, 0.5%, or even 0.1% of the specified amount. It is contemplated that, at each instance, such terms may be replaced with the notation " $\pm 10\%$ ", or the

like (or by indicating a variance of a specific amount calculated based on the relevant value). It is also contemplated that, at each instance, such terms may be deleted.

For the avoidance of doubt, the dose administered to a subject, particularly a human subject, in the context of the present invention should be sufficient to effect a therapeutic response in the subject over a reasonable timeframe. One skilled in the art will recognize that the selection of the exact dose and composition and the most appropriate delivery regimen will also be influenced by *inter alia* the pharmacological properties of the formulation, the nature and severity of the condition being treated, and the physical condition and mental acuity of the recipient, as well as the potency of the specific compound, the age, condition, body weight, sex and response of the subject to be treated, and the stage/severity of the disease.

In any event, the medical practitioner, or other skilled person, will be able to determine routinely the actual dosage which will be most suitable for an individual subject. The above-mentioned dosages are exemplary of the average case; there can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

Combinations and kits-of-parts

The skilled person will understand that treatment with compounds of the invention may further comprise (i.e. be combined with) further treatment(s) for the same condition.

In particular, compounds of the invention may also be combined with one or more other (i.e. different) therapeutic agents (i.e. agents that are not compounds of the invention) that are useful in the treatment a disorder or condition ameliorated by the activation of AMPK. Such combination products that provide for the administration of a compound of the invention in conjunction with one or more other therapeutic agent may be presented either as separate formulations, wherein at least one of those formulations comprises a compound of the invention, and at least one comprises the other therapeutic agent, or may be presented (i.e. formulated) as a combined preparation (i.e. presented as a single formulation including a compound of the invention and the one or more other therapeutic agent).

Thus, according to a third aspect of the invention, there is provided a combination product comprising:

(I) a compound of the invention, as hereinbefore defined (i.e. in the first aspect of the invention, including all embodiments and particular features thereof); and
(II) one or more other therapeutic agents that is useful in the treatment of a disorder or condition ameliorated by the activation of AMPK (e.g. a cardiovascular disease (such as heart failure), diabetic kidney disease and the like, as described herein),

wherein each of components (I) and (II) is formulated in admixture, optionally with one or more pharmaceutically acceptable excipients.

In a fourth aspect of the invention, there is provided a kit-of-parts comprising:

(a) a pharmaceutical formulation as hereinbefore defined (i.e. in the second aspect of the invention); and
(b) one or more other therapeutic agents that is useful in the treatment of a disorder or condition ameliorated by the activation of AMPK (e.g. a cardiovascular disease (such as heart failure), diabetic kidney disease and the like, as described herein), optionally in admixture with one or more pharmaceutically-acceptable excipients,

which components (a) and (b) are each provided in a form that is suitable for administration in conjunction (i.e. concomitantly or sequentially) with the other.

With respect to the kits-of-parts as described herein, by "administration in conjunction with" (and similarly "administered in conjunction with") we include that the respective formulations are administered, sequentially, separately or simultaneously, as part of a medical intervention directed towards treatment of the relevant condition.

Thus, in relation to the present invention, the term "administration in conjunction with" (and similarly "administered in conjunction with") includes that the two active ingredients (i.e. a compound of the invention and a further agent for the treatment of a disorder or condition ameliorated by the activation of AMPK, or compositions comprising the same) are administered (optionally repeatedly) either together, or sufficiently closely in time, to enable a beneficial effect for the patient, that is greater, over the course of the treatment of the relevant condition, than if either agent is administered (optionally repeatedly) alone, in the absence of the other component, over the same course of treatment. Determination of whether a combination provides a greater beneficial effect in respect of, and over the course of, treatment of a particular

condition will depend upon the condition to be treated, but may be achieved routinely by the skilled person.

Further, in the context of the present invention, the term "in conjunction with" includes that one or other of the two formulations may be administered (optionally repeatedly) prior to, after, and/or at the same time as, administration of the other component. When used in this context, the terms "administered simultaneously" and "administered at the same time as" includes instances where the individual doses of the compound of the invention and the additional compound for the treatment of a disorder or condition ameliorated by the activation of AMPK, or pharmaceutically acceptable salts thereof, are administered within 48 hours (e.g. within 24 hours, 12 hours, 6 hours, 3 hours, 2 hours, 1 hour, 45 minutes, 30 minutes, 20 minutes or 10 minutes) of each other.

Other therapeutic agents useful in the treatment of a disorder or condition ameliorated by the activation of AMPK (such as heart failure, diabetic kidney disease and the like, as described herein) will be well-known to those skilled in the art. Preferably the other therapeutic agent will be selected from the group consisting of biguanide antihyperglycemic agents and sodium-glucose transport protein 2 (SGLT2) inhibitors (and pharmaceutically acceptable salts and solvates thereof).

Biguanide antihyperglycemic agents that may be mentioned include phenformin, buformin and, particularly, metformin (and pharmaceutically acceptable salts thereof). Thus, in one embodiment, a compound of the invention may be provided in combination with metformin (or a pharmaceutically acceptable salt thereof) in order to treat any of the diseases disclosed herein.

The skilled person will understand that a sodium-glucose transport protein 2 inhibitor is a substance or agent that elicits a decrease in one or more functions of sodium-glucose transport protein 2, and by "decrease in the functions of sodium-glucose transport protein 2" we include the cessation of one or more functions of sodium-glucose transport protein 2, or a reduction in the rate of a particular function. A particular function that may be fully or partially inhibited is the ability of sodium-glucose transport protein 2 to act as a glucose transporter.

In particular embodiments, the sodium-glucose transport protein 2 inhibitor is a gliflozin. Gliflozins are a known class of small-molecule sodium-glucose transport protein 2 inhibitors. Hawley et al. (Diabetes, 2016, 65, 2784–2794) and Villani et al.

(Molecular Metabolism, 2016, 5, 1048–1056) have recently discussed the possible mechanisms of action of certain gliflozins. Particular gliflozins which may be mentioned include, canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, tofogliflozin, sergliflozin (such as sergliflozin etabonate), remogliflozin (such as remogliflozin etabonate),
5 ertugliflozin and sotagliflozin, and pharmaceutically acceptable salts and solvates thereof.

Medical uses

10 As indicated herein, the compounds of the invention are useful as pharmaceuticals. Compounds of the invention are useful because they possess pharmacological activity, and/or are metabolised in the body following oral or parenteral administration to form a compound that possesses pharmacological activity.

15 Thus, according to a fifth aspect of the invention there is provided a compound of the invention, as hereinbefore defined (i.e. a compound as defined in the first aspect of the invention), or a pharmaceutical formulation, combination product or kit of parts as defined in respect of the second, third and fourth aspects of the invention, for use in medicine. For the avoidance of doubt, references to compounds as defined in the first
20 aspect of the invention include references to compounds of formula I (including all embodiments thereof) and pharmaceutically acceptable salts and solvates thereof.

Compounds of the invention (i.e. a compound as defined in the first aspect of the invention), and formulations, combination products and kits containing the same, may
25 be particularly useful in treating a disorder or condition ameliorated by the activation of AMP-activated protein kinase (AMPK). Thus, in a sixth aspect of the invention, there is provided a compound of the invention, or a formulation comprising said compound, for use in the treatment of a disorder or condition ameliorated by the activation of AMPK.

30 Similarly, there is provided the use of a compound of the invention, or a formulation comprising said compound, in the manufacture of a medicament for the treatment of a disorder or condition ameliorated by the activation of AMPK. In a further alternative sixth aspect of the invention, there is provided a method of treating a disorder or
35 condition ameliorated by the activation of AMPK comprising administering a compound of the invention (or a formulation comprising said compound) to a subject (e.g. a human) in need thereof.

By 'activate AMPK', we mean that the steady state level of phosphorylation of the Thr-172 moiety of the AMPK- α (AMPK-alpha) subunit is increased compared to the steady state level of phosphorylation in the absence of a compound of formula I or an active metabolite thereof (e.g. 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide). Alternatively, or in addition, we mean that there is a higher steady state level of phosphorylation of any other proteins downstream of AMPK, such as acetyl-CoA carboxylase (ACC).

The terms "disorder or condition ameliorated by the activation of AMPK" will be understood by those skilled in the art to include cardiovascular disease (such as heart failure), diabetic kidney disease, diabetes (such as type 2 diabetes), insulin resistance, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, pain, opioid addiction, obesity, cancer, inflammation (including chronic inflammatory diseases), autoimmune diseases, osteoporosis and intestinal diseases. Other diseases or conditions that may be ameliorated by the activation of AMPK include hyperinsulinemia and associated conditions, a condition/disorder where fibrosis plays a role, sexual dysfunction and neurodegenerative diseases.

The term "cancer" will be understood by those skilled in the art to include one or more diseases in the class of disorders that is characterized by uncontrolled division of cells and the ability of these cells to invade other tissues, either by direct growth into adjacent tissue through invasion, proliferation or by implantation into distant sites by metastasis. By "proliferation" we include an increase in the number and/or size of cancer cells. By "metastasis" we mean the movement or migration (e.g. invasiveness) of cancer cells from a primary tumor site in the body of a subject to one or more other areas within the subject's body (where the cells can then form secondary tumors).

Thus, compounds of the invention may be suitable for use in the treatment of any cancer type, including all tumors (non-solid and, preferably, solid tumors, such as carcinoma, adenoma, adenocarcinoma, blood cancer, irrespective of the organ). For example, the cancer cells may be selected from the group consisting of cancer cells of the breast, bile duct, brain, colon, stomach, reproductive organs, thyroid, hematopoietic system, lung and airways, skin, gallbladder, liver, nasopharynx, nerve cells, kidney, prostate, lymph glands and gastrointestinal tract. Preferably, the cancer is selected from the group consisting of colon cancer (including colorectal adenomas), breast cancer (e.g. postmenopausal breast cancer), endometrial cancer, cancers of the hematopoietic system (e.g. leukemia, lymphoma, etc.), thyroid cancer, kidney cancer, oesophageal adenocarcinoma, ovarian cancer, prostate cancer, pancreatic cancer,

gallbladder cancer, liver cancer and cervical cancer. More preferably, the cancer is selected from the group consisting of colon, prostate and, particularly, breast cancer. Where the cancer is a non-solid tumor, it is preferably a hematopoietic tumor such as a leukemia (e.g. Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphocytic Leukemia (ALL), or Chronic Lymphocytic Leukemia (CLL). Preferably the cancer cells are breast cancer cells.

The term "diabetes" (i.e. diabetes mellitus) will be understood by those skilled in the art to refer to both type 1 (insulin-dependent) diabetes and type 2 (insulin-independent) diabetes, both of which involve the malfunction of glucose homeostasis. The compounds of the invention and formulations thereof may be particularly suitable for use in the treatment of type 1 diabetes and/or type 2 diabetes. The compounds of the invention are particularly suited for the treatment of type 2 diabetes.

As well as being useful in the treatment of diabetes, the compounds of the invention are also suitable for treating diabetic kidney disease (i.e. diabetic nephropathy). "Diabetic kidney disease" refers to kidney damage caused by diabetes and is a serious complication of type 1 diabetes and type 2 diabetes. Diabetic kidney disease affects the kidneys' ability to remove waste products from blood to be excreted as urine, and can lead to kidney failure.

Moreover, the compounds of the invention are also suitable for treating chronic kidney disease, including chronic kidney disease in the absence of type 2 diabetes. "Chronic kidney disease" is a condition characterised by a gradual loss of kidney function over time. Chronic kidney disease usually occurs as a result of one or more other diseases or conditions that affect the kidneys, such as high blood pressure, diabetes, high cholesterol, kidney infections, glomerulonephritis, polycystic kidney disease, obstruction of the urinary tract blockages in the flow of urine and long-term medication use.

The term "hyperinsulinemia or an associated condition" will be understood by those skilled in the art to include hyperinsulinemia, type 2 diabetes, glucose intolerance, insulin resistance, metabolic syndrome, dyslipidemia, hyperinsulinism in childhood, hypercholesterolemia, high blood pressure, obesity, fatty liver conditions, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, cardiovascular disease, atherosclerosis, cerebrovascular conditions such as stroke, systemic lupus erythematosus, neurodegenerative diseases such as Alzheimer's disease, and

polycystic ovary syndrome. Other disease states include progressive renal disease such as chronic renal failure.

5 In particular, compounds of the invention and formulations thereof may be suitable for use in the treatment of obesity associated with hyperinsulinemia and/or cardiovascular disease associated with hyperinsulinemia.

10 Compounds of the invention and formulations thereof may also be suitable for use in the treatment of cardiovascular disease, such as heart failure, wherein said cardiovascular disease is not associated with hyperinsulinemia. Similarly, compounds of the invention and formulations thereof may also be suitable for use in the treatment of obesity which is not associated with hyperinsulinemia. For the avoidance of doubt, the treatment of obesity and/or cardiovascular disease (such as heart failure) where AMPK activation may be beneficial is included within the scope of the invention.

15 A condition/disorder where fibrosis plays a role includes (but is not limited to) scar healing, keloids, scleroderma, pulmonary fibrosis (including idiopathic pulmonary fibrosis), nephrogenic systemic fibrosis, and cardiovascular fibrosis (including endomyocardial fibrosis), systemic sclerosis, liver cirrhosis, eye macular degeneration, 20 retinal and vitreal retinopathy, Crohn's/inflammatory bowel disease, post-surgical scar tissue formation, radiation and chemotherapeutic-drug induced fibrosis, and cardiovascular fibrosis.

25 The compounds of invention may also be useful in the treatment of sexual dysfunction (e.g. the treatment of erectile dysfunction). The compounds of invention may also be useful in the treatment of inflammation.

30 Neurodegenerative diseases that may be mentioned include Alzheimer's disease, Parkinson's disease and Huntington's disease, amyotrophic lateral sclerosis, polyglutamine disorders, such as spinal and bulbar muscular atrophy (SBMA), dentatorubral and pallidoluysian atrophy (DRPLA), and a number of spinocerebellar ataxias (SCA).

35 Compounds of the invention may be useful in the treatment of a non-alcoholic fatty liver disease (NAFLD).

Non-alcoholic fatty liver disease (NAFLD) is defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver (designated as an accumulation of

greater than 5% of hepatocytes histologically). It is the most common liver disorder in developed countries (for example, affecting around 30% of US adults) and most patients are asymptomatic. If left untreated, the condition may progressively worsen and may ultimately lead to cirrhosis of the liver. NAFLD is particularly prevalent in obese patients, with around 80% thought to have the disease.

NAFLD may be diagnosed wherein alcohol consumption of the patient is not considered to be a main causative factor. A typical threshold for diagnosing a fatty liver disease as "not alcohol related" is a daily consumption of less than 20 g for female subjects and less than 30 g for male subjects.

Particular diseases or conditions that are associated with NAFLD include metabolic conditions such as diabetes, hypertension, obesity, dyslipidemia, abetalipoproteinemia, glycogen storage diseases, Weber-Christian disease, acute fatty liver of pregnancy, and lipodystrophy. Other non-alcohol related factors related to fatty liver diseases include malnutrition, total parenteral nutrition, severe weight loss, refeeding syndrome, jejunoileal bypass, gastric bypass, polycystic ovary syndrome and diverticulosis.

Non-alcoholic steatohepatitis (NASH) is the most aggressive form of NAFLD, and is a condition in which excessive fat accumulation (steatosis) is accompanied by inflammation of the liver. If advanced, NASH can lead to the development of scar tissue in the liver (fibrosis) and, eventually, cirrhosis. As described above, the compounds of the invention have been found to be useful in the treatment of NAFLD and inflammation. It follows that the compounds of the invention are also useful in the treatment of NASH. Therefore, in a further embodiments, the treatment is of non-alcoholic steatohepatitis (NASH).

It has been shown that AMPK activator compounds (such as 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide (i.e. the compound of formula II)) are capable of treating pain (Das V, *et al.* Reg Anesth Pain Med 2019;0:1–5. doi:10.1136/rapm-2019-100839 and Das V, *et al.* Reg Anesth Pain Med 2019;0:1–6. doi:10.1136/rapm-2019-100651) and such compounds may be considered to be analgesics. It therefore follows that, since the compounds of the invention are capable of activating AMPK, or are metabolised *in vivo* to form a known AMPK activator compound, the compounds of the invention may be useful in the treatment of pain. In particular, the compounds of the invention may be useful in the treatment of patients with severe pain, chronic pain or useful in the management of pain after surgery.

Opioid-based therapies, such as opioid analgesics, are used to treat severe, chronic cancer pain, acute pain (e.g. during recovery from surgery and breakthrough pain) and their use is increasing in the management of chronic, non-malignant pain. However, the increasing use of opioid-based therapies to treat pain has resulted in an increase of opioid dependence (e.g. opioid addiction). As AMPK activators, the compounds of the invention may be used to treat pain in place of an opioid-based therapy, as known by those skilled in the art. Accordingly, the compounds of the invention may be useful in treating opioid addiction.

Particular autoimmune diseases known to those skilled in the art include Crohn's/inflammatory bowel disease, systemic lupus erythematosus and type 1 diabetes.

Particular intestinal diseases that should be mentioned include Crohn's/inflammatory bowel disease and cancer of gastrointestinal tract.

The skilled person will understand that references to the "treatment" of a particular condition (or, similarly, to "treating" that condition) will take their normal meanings in the field of medicine. In particular, the terms may refer to achieving a reduction in the severity and/or frequency of occurrence of one or more clinical symptom associated with the condition, as judged by a physician attending a subject having or being susceptible to such symptoms.

The skilled person will understand that such treatment or prevention will be performed in a subject in need thereof. The need of a subject for such treatment or prevention may be assessed by those skilled in the art using routine techniques. In the context of the present invention, a "subject in need" of the compound of the invention includes a subject that is suffering a disorder or condition ameliorated by the activation of AMPK. As used herein, the terms "disease" and "disorder" (and, similarly, the terms condition, illness, medical problem, and the like) may be used interchangeably.

Without wishing to be bound by theory, it is believed that the administration of a compound of the invention enhances the bioavailability of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide in the systemic circulation. Administration of formulations comprising a compound of the invention has been shown to provide an approximately two-fold increase in the plasma concentration of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-

yl]benzamide under certain circumstances compared to administration of a formulation that comprises 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide.

5 Compounds of the invention (and formulations thereof) may have the advantage that they may be more efficacious than, be less toxic than, be longer acting than, be more potent than, produce fewer side effects than, be more easily absorbed than, and/or have a better pharmacokinetic profile (e.g. higher oral bioavailability and/or lower clearance) than, and/or have other useful pharmacological, physical, or chemical
10 properties over, other therapies known in the prior art, whether for use in the above-stated indications or otherwise. In particular, compounds of the invention may have the advantage that they are more efficacious and/or exhibit advantageous properties *in vivo*.

15 **Figures**

The following drawings are provided to illustrate various aspects of the present inventive concept and are not intended to limit the scope of the present invention unless specified herein.

20

Figure 1 shows western blot images that demonstrate that Compounds 3 and 5 increase phosphorylation of AMPK in a dose-dependent manner.

Figure 2 shows comparative results of oral pharmacokinetic studies using Compound 1
25 and Compound 3.

Examples

The present invention is explained in greater detail in the following non-limiting
30 examples.

The reaction schemes described below are intended to provide a general description of the methodology employed in the preparation of the compounds of the invention. The examples provided herein are offered to illustrate but not limit the compounds of the
35 invention, as well as the preparation of such compounds and intermediates.

All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents and catalysts utilised to synthesise the compounds of the invention are either

commercially available or can be routinely prepared by procedures described in the literature, for example, Houben-Weyl "Science of Synthesis" volumes 1-48, Georg Thieme Verlag, and subsequent versions thereof.

- 5 A reaction may be carried out in the presence of a suitable solvent or diluent or of mixture thereof in a manner known to those skilled in the art of organic synthesis. A reaction may also be carried out, if needed, in the presence of an acid or a base, with cooling or heating, for example in a temperature range from about -30 °C to about 150 °C. In some embodiments, a reaction is carried out in a temperature range from
10 about 0 °C to about 100 °C, and more particularly, in a temperature range from room temperature to about 80 °C, in an open or closed reaction vessel and/or in the atmosphere of an inert gas, for example nitrogen.

Abbreviations

- 15 Abbreviations as used herein will be known to those skilled in the art. In particular, the following abbreviations may be used herein.

	AUC:	Area under the concentration-time curve
	aq:	Aqueous
20	b.w.:	Body weight
	C _{max} :	Peak plasma concentration
	d:	Doublet
	DCM:	Dichloromethane
	DMF:	Dimethylformamide
25	DMAP:	4-Dimethylaminopyridine
	DMSO:	Dimethylsulfoxide
	ESI:	Electrospray ionisation
	Et ₃ N:	Triethylamine
	EtOH:	Ethanol
30	g:	Gram
	h:	Hours
	HPLC:	High performance liquid chromatography
	LC:	Liquid chromatography
	LCMS:	Liquid chromatography – mass spectrometry
35	LC-MS/MS:	Liquid chromatography – (tandem) mass spectrometry
	LLOQ:	Lower limit of quantification
	m:	Multiplet
	MeOD:	Methanol-d ₄

	Min:	Minutes
	mL:	Millilitre
	MRT:	Mean residence time
	<i>n</i> Bu ₃ N:	Tributylamine
5	ND:	Not detected
	NMR:	Nuclear magnetic resonance
	RT:	Room temperature
	s:	Singlet
	T _{1/2} :	Half-life
10	T _{max} :	Time to reach the peak plasma concentration
	THF:	Tetrahydrofuran
	TLC:	Thin-layer chromatography

Instrumentation Conditions


LC Parameters

Column:	Agilent Zorbax SB-C8, 50 x 4.6 mm, 350 µm
Mobile phase:	5 mM ammonium acetate:methanol with 0.1% formic acid (15:85 v/v)
Separation mode:	Isocratic
Flow rate:	0.800 mL/min
Injection volume:	2 µL
Auto sampler temperature:	4 °C
Column oven temperature:	40 °C
LC-MS/MS	Shimadzu LCMS-8045
Source	ESI
Polarity	Positive
m/z of analyte (Compound 1)	379.800 > 89.100
m/z of internal standard (warfarin)	309.100 > 251.100

15

The present invention will be further described by reference to the following examples, which are not intended to limit the scope of the invention.

Example 1: preparation of 4-((5Z)-5-[(4-chlorobenzoyl)imino]-2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-4-yl)methoxy)-4-oxobutanoic acid



5

Compound 1: 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide

Compound 1 was prepared in accordance with the procedures described in WO 2011/004162.

10

Compound 2: 4-chloro-N-{2-[(4-chlorophenyl)methyl]-4-(hydroxymethyl)-3-oxo-1,2,4-thiadiazolidin-5-ylidene}benzamide

To a stirring solution of Compound 1 (10 g, 0.026 mol) in DMF (200 mL) were added Et_3N (15 mL, 0.105 mol) and 37% formaldehyde (8.5 mL, 0.105 mol). The reaction mixture was stirred at RT for 12 to 14 h.

15

The reaction mixture was then concentrated to remove the DMF. The crude material obtained was slurried in water (100 mL) for 30 minutes. The slurry was filtered and dried at ambient temperature to yield Compound 2 as white solid (9.6 g, 90.5% yield).

20

Compound 3: 4-((5Z)-5-[(4-chlorobenzoyl)imino]-2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-4-yl)methoxy)-4-oxobutanoic acid

To a stirring solution of Compound 2 (10 g, 0.024 mol) in THF (200 mL) were added DMAP (0.44 g, 0.004 mol) and succinic anhydride (7.29 g, 0.072 mol). The reaction mixture was stirred at RT for 12h.

25


After completion (as observed by TLC), the reaction mixture was concentrated to remove the THF. The crude material obtained was diluted with THF (100 mL), stirred for 1h at RT and filtered to afford Compound 3 as a white solid (7.3 g, 59% yield).

¹H NMR (300 MHz, MeOD) δ (ppm): 2.61 (m, 4H), 4.72 (s, 2H), 6.10 (s, 2H), 7.29 (dd, 4H), 7.41 (d, 2H), 8.12 (d, 2H).

LCMS : 510.4 [M+H].

HPLC: >98% purity at 13.6 minutes.

Example 2: preparation of disodium {(5Z)-5-[(4-chlorobenzoyl)imino]-2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-4-yl}methyl phosphate



Compound 2: 4-chloro-N-{2-[(4-chlorophenyl)methyl]-4-(hydroxymethyl)-3-oxo-1,2,4-thiadiazolidin-5-ylidene}benzamide

Compound 2 was prepared in accordance with the procedure described in Example 1.

Compound 4: 4-chloro-N-{4-(chloromethyl)-2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-5-ylidene}benzamide

A mixture of Compound 2 (10 g, 0.0243 mol) and thionyl chloride (60 mL) was heated to 75 °C over a period of 3h.

After completion (as observed by TLC), the reaction mixture was concentrated and the crude product was washed with diethyl ether (3 x 100 mL) to afford Compound 4 as a white solid (9.5 g, 90 % yield).

Compound 5: disodium {(5Z)-5-[(4-chlorobenzoyl)imino]-2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-4-yl}methyl phosphate

To a stirring solution of phosphoric acid (85 %, 15.1 g, 0.154 mol) in ethanol (60 mL), tributylamine (83 mL, 0.35 mol) was added at ambient temperature. The solvent was removed by evaporation and the residue was dissolved in DCM (60 mL). The DCM solution was dried over sodium sulphate, filtered and evaporated to afford di-tributyl-ammonium dihydrogen phosphate.

A mixture of Compound 4 (3.0 g, 0.007 mol) and the above prepared tributyl-ammonium dihydrogen phosphate was taken in DCM (60 mL) and stirred for 10 min. The reaction mixture was distilled off at 40 °C and the residue obtained was heated at 60 °C on a water bath for 10 to 15 minutes. The residue was re-dissolved in DCM (6 mL), the DCM was distilled off and residue obtained was heated at 60 °C on a water bath for 10 to 15 min. The above procedure was repeated for four times.

After completion (as observed by TLC), the residue was dissolved in DCM (4 mL) and washed with water (3x4 mL). The organic phase was separated, dried over sodium sulphate, filtered and concentrated. The crude product obtained upon evaporation was taken in water and basified (pH 9 to 9.5) with 0.2 M sodium hydroxide. After basification, the mixture was filtered and filtrate was lyophilized to yield Compound 5 as a white solid (0.6 g, 17.5% yield).

¹H NMR (300 MHz, DMSO-D₆) δ (ppm): 4.78 (s, 2H), 5.55 (s, 2H), 7.40 (dd, 4H), 7.55 (d, 2H), 8.19 (d, 2H).

LCMS: 490.1 [M+H].

HPLC: >98% purity at 8.2 minutes.

Example 3 – Solubility of compounds at different pH

Methods

Approximately 5 mg of each test compound (Compounds 1 and 5) was weighed in duplicate, and each weighed sample was transferred to a separate centrifuge tube containing 5 mL of the respective buffer. All the tubes were tightly stoppered and agitated at a constant rate at 30 ± 1 °C using an orbital shaker.

After 24 hours, one tube of each buffer solution was removed from the shaker. 50 µL of the buffer solution from each removed tube was transferred into a 10 mL tube and made up to the mark with diluent. Then 2.5 mL of the supernatant of each tube was transferred into a 50 mL tube and made up to 25 mL.

The nominal concentration of the solution in each 50 mL tube was 5 µg/mL.

Linearity solutions of 40 ng/mL to 10000 ng/mL were plotted.

5

Results

The results for the solubility experiments are tabulated in Tables 1 and 2 below.

10 The results show that Compound 5 has a higher solubility compared to Compound 1 in basic solutions (i.e. pH >7) as well as in mildly acidic conditions. In particular, Compound 5 is up to 30-times more soluble in basic solution compared to Compound 1.

Absolute Solubility: 2 hours incubation		
Buffer	Solubility (mg/mL)	
	Compound 1	Compound 5*
HCl Buffer, pH: 1.20	ND	ND
Acetate Buffer, pH: 4.50	ND	0.015
Phosphate Buffer, pH: 7.40	ND	0.119
Alkaline Borate Buffer, pH: 9.20	0.029	0.720
Ultrapure water	ND	0.419

Note: ND indicates not detected, concentration was below LLOQ;

* HPLC was analysis performed for Compound 5

15

Table 1. Results of a Two-hour Solubility Study of Compounds 1 and 5

Absolute Solubility: 20 hours incubation		
Buffer	Solubility (mg/mL)	
	Compound 1	Compound 5*
HCl Buffer, pH; 1.20	ND	ND
Acetate Buffer, pH: 4.50	ND	0.015
Phosphate Buffer, pH: 7.40	ND	0.098
Alkaline Borate Buffer, pH :9.20	0.044	1.239
Ultrapure water	ND	0.036

Note: ND indicates not detected, concentration was below LLOQ;

* HPLC was analysis performed for Compound 5

20

Table 2. Results of a Twenty-hour Solubility Study of Compounds 1 and 5

Example 4 – Stability of compounds

5 $5\ \mu\text{M}$ solutions of Compounds 1, 3 and 5 in USP buffer (pH: 7.40) were prepared with 5 mM DMSO stock solutions. The solutions were incubated at 37 °C for 120 minutes, with shaking at 400 rpm using a thermomixer.

After 0, 15, 30, 60 and 120 minute intervals, aliquots of sufficient volume of the compound solutions were taken, diluted to the final concentration and analysed.

Results

The results for the stability experiments are tabulated in Table 3 below.

15 The results show that Compounds 3 and 5 possess comparable stability to Compound 1 in mildly basic solutions (i.e. pH = 7.4).

Test Compound	% remaining compared to 0.0 min				
	0.0 min	15 min	30 min	60 min	120 min
Compound 1	100.00	97.62	101.31	99.41	106.18
Compound 3	100.00	86.96	93.61	88.74	75.40
Compound 5	100.00	103.92	107.58	107.88	97.30

Table 3. Comparative Stability Data in Phosphate Buffer (pH: 7.40)

Example 5 – Activation of AMPK*Cultivation and Compound Treatment of INS-1E Insulinoma Cells*

20 INS-1E cells were cultivated as described in Steneberg *et al.*, JCI Insight. 2018;3(12):e99114. <https://doi.org/10.1172/jci.insight.99114>, using 5% instead of 25 10% fetal bovine serum when plated for treatment.

Compound 3 was dissolved at 10 mM in DMSO and frozen at -20 °C.

30 Compound 5 was dissolved at 10 mM in a 50:50 water/DMSO mixture, incubated for 15 minutes at room temperature in ultrasonic bath (VWR ultrasonic cleaner), and stored at room temperature.

The INS-1E cells were treated in serum free medium with increasing doses of Compounds 3 and 5 for 4 and 16 hours, respectively, in accordance with the methods

described in Steneberg *et al.*, JCI Insight. 2018;3(12):e99114. <https://doi.org/10.1172/jci.insight.99114>.

Western Blot analysis

5

Western blot analysis of the INS-1E cells was performed as described in Steneberg *et al.*, JCI Insight. 2018;3(12):e99114. <https://doi.org/10.1172/jci.insight.99114>. The cell lysates were passed through a 30-gauge needle, ~8-times and centrifuged for 10 min at +4 °C at 14000 rpm. Quantified values for AMPK α , and phosphorylated-T172 AMPK α , were normalized toward the quantified values for β -Actin.

10

Results

The results for Western blot analysis are tabulated in Table 3 below and are shown graphically in Figure 1.

15

The results show that Compounds 3 and 5 increase phosphorylated-T172 AMPK in a dose-dependent manner in cultured INS-1E cells. Compounds 3 and 5 are therefore agonists of AMPK.

Compound	Time	Control	2.5 μ M	5 μ M	10 μ M
3 (0.1% DMSO)	4 h	1.00	1.62	1.88	2.95
5 (0.05% DMSO)	16 h	1.00	1.29	1.62	3.21

20

Table 4. The ratio between p-T172 AMPK and non-phosphorylated AMPK

Example 6 - Single Dose Oral Pharmacokinetic Study of Compounds 1 and 3 in Sprague Dawley Rats

25 *Formulation of Compound 1*

10.0 mL of 2% w/v methyl cellulose solution in phosphate buffer (pH 7.5) was added to a 100 mL conical flask along with 1 g of 2 mm glass beads. The solution was vigorously stirred on a magnetic stirrer. 100 mg of Compound 1 was slowly added to the solution, and the solution was vigorously stirred for approximately 1h. The pH of the formulation was measured to be 7.49. Each formulation was freshly prepared prior to administration to the animals. The final concentration of Compound 1 in of the formulation was 10 mg/mL. The formulation was administered at 5 mL/kg body weight.

30

35 *Formulation of Compound 3*

10.0 mL of 2% w/v methyl cellulose solution in phosphate buffer (pH 7.5) was added to a 100 mL of conical flask together with 1 g of 2 mm glass beads. The solution was vigorously stirred on a magnetic stirrer. 134 mg of Compound 3 was slowly added to the solution, and the solution was vigorously stirred for approximately 1h. The pH of the formulation was measured to be 7.44. Each formulation was freshly prepared prior to administration to the animals. The final concentration of Compound 3 in the formulation was 13.4 mg/mL, which is equivalent to 10 mg/mL of Compound 1. The formulation was administered at 5 mL/kg body weight.

10 *Dose selection and justification for selection*

The doses of 50 mg/kg and 67 mg/kg b.w. for Compound 1 and Compound 3, respectively, were selected for comparison of equimolar doses.

Dose Administration

15 Adult healthy male Sprague Dawley rats aged 9 to 11 weeks were used for experimentation after a minimum three days of acclimatisation. Fed state animals were administered the formulation of Compound 1 or Compound 3 orally *via* gavage at a dose of 50 mg/kg or 67 mg/kg body weight, respectively.

20 *Blood Sampling*

Under mild isoflurane anesthesia, blood specimens were collected by retro-orbital puncture method using capillary tubes into pre-labeled tubes containing anticoagulant (K₂EDTA: 2 mg/mL blood) during the next 72 hours post-dosing, as detailed in Table 6. For blood sampling at multiple time points, the right and left eyes were used alternatively. Collected blood specimens were centrifuged at 6000 rpm, 4 °C for 10 minutes and the plasma samples were separated and stored at -80 °C until analysis.

Results

The results for the single dose oral pharmacokinetic study in rats are tabulated in Tables 4 and 5 below and are shown graphically in Figure 2. In Table 4, the C_{max}, T_{max}, AUC_{last}, AUC_{inf}, AUC_{extrap}, T_{1/2} and MRT_{last} values are for 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide (Compound 1), which was detected following the administration of both Compounds 1 and 3.

35 The results show that there is a surprising two-fold increase in the systemic exposure of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide when Compound 3 is administered compared to Compound 1. Thus, the systemic

exposure of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide is increased by administration of a compound of the invention.

Compound No.	1	3
Dose (mg/kg b.w.)	50	67 (equivalent to 50 of Compound 1)
C_{max} ($\mu\text{g/mL}$)	19.60 ± 5.54	40.80 ± 5.66
T_{max} (h)	7.33 ± 1.16	7.33 ± 1.16
AUC_{last} ($\text{h} \cdot \mu\text{g/mL}$)	449.40 ± 157.75	847.34 ± 99.98
AUC_{inf} ($\text{h} \cdot \mu\text{g/mL}$)	458.31 ± 154.77	880.35 ± 91.70
AUC_{extrap} (%)	2.33 ± 1.74	3.80 ± 3.53
$T_{1/2}$ (h)	8.42 ± 1.47	9.59 ± 2.96
MRT_{last} (h)	14.78 ± 0.68	14.66 ± 1.45

Table 5. Mean Plasma Pharmacokinetic Parameters Following Administration of Compounds 1 and 3

5

	Plasma concentration of Compound 1 (µg/mL)				
	Time (h)	Compound 1		Compound 3	
		Mean	SD	Mean	SD
	0.00	0.00	0.00	0.00	0.00
	0.25	0.62	0.62	1.13	0.13
	0.50	1.98	0.59	5.53	0.73
	1.00	4.24	1.84	9.51	0.74
	2.00	7.99	4.49	16.17	1.53
	4.00	14.01	5.73	23.83	4.56
	6.00	17.00	5.30	35.17	4.85
	8.00	19.33	5.33	38.83	8.82
	24.00	9.44	4.43	16.03	1.82
48.00	0.72	0.17	2.12	1.30	
72.00	0.00	0.00	0.00	0.00	
Lower limit of quantification of Compound 1				0.5 µg/mL	

Table 6. Plasma Concentration of Compounds 1 and 3

Example 7 - Single Dose Oral Pharmacokinetic Study of Compound 5 in Sprague Dawley Rats

Formulation of Compound 5

5 6.0 mL of 2% w/v methyl cellulose solution in phosphate buffer (pH 7.5) was added to a 100 mL of conical flask together with 1 g of 2 mm glass beads. The solution was vigorously stirred on a magnetic stirrer. 77 mg of Compound 5 was slowly added to the solution, and the solution was vigorously stirred for approximately 1h. The pH of the formulation was measured to be 7.43. The formulation was freshly prepared prior
10 to administration to the animals.

Dose Administration

Adult healthy male Sprague Dawley rats aged 9 to 11 weeks were used for experimentation after a minimum three days of acclimatisation. Fed state animals
15 were administered the formulation of Compound 5 orally *via* gavage at a dose of 64 mg/kg body weight (5 mL/kg dose volume).

Blood Sampling

Under mild isoflurane anesthesia, blood specimens were collected by retro-orbital
20 puncture method using capillary tubes into pre-labeled tubes containing anticoagulant (K₂EDTA: 2 mg/mL blood) during the next 72 hours post-dosing. For blood sampling at multiple time points, the right and left eyes were used alternatively. Collected blood specimens were centrifuged at 6000 rpm, 4 °C for 10 minutes and the plasma samples were separated and stored at -80 °C until analysis.

25

Results

The results for the single dose oral pharmacokinetic study in rats are tabulated in Tables 7 and 8 below. In Table 7, the C_{max}, T_{max}, AUC_{last}, AUC_{inf}, AUC_{extrap}, T_{1/2} and MRT_{last} values are for 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-
30 5-yl]benzamide (Compound 1), which was detected following the administration of Compound 5. Thus, Compound 5 acts as a prodrug of Compound 1.

Compound No.	5
Dose (mg/kg b.w.)	64
C _{max} (µg/mL)	30.77 ± 9.68
T _{max} (h)	6.00 ± 0.0
AUC _{last} (h*µg/mL)	612.21 ± 376.22
AUC _{inf} (h*µg/mL)	688.74 ± 315.05
AUC _{extrap} (%)	15.22 ± 14.63
T _{1/2} (h)	9.09 ± 2.87
MRT _{last} (h)	11.72 ± 3.69


Table 7. Mean Plasma Pharmacokinetic Parameters Following Administration of Compound 5

	Plasma concentration of Compound 1 (µg/mL)		
	Time (h)	Compound 5	
		Mean	SD
	0.00	0.00	0.00
	0.25	0.84	0.20
	0.50	2.39	0.50
	1.00	4.78	1.42
	2.00	11.09	2.17
	4.00	23.97	10.19
	6.00	30.77	9.68
	8.00	29.23	10.80
	24.00	13.84	10.73
	48.00	0.23	0.40
	72.00	0.00	0.00
Lower limit of quantification of Compound 1			0.5 µg/mL

5 Table 8. Plasma Concentration of Compound 1 Following Administration of Compound 5

Claims


1. A compound of formula I,



5


wherein R¹ is selected from the group consisting of -C(O)-C₂H₄-CO₂H and -PO₃H₂, or a pharmaceutically acceptable salt or solvate thereof.

- 10 2. The compound according to Claim 1 wherein, the compound of formula I is:



or a pharmaceutically acceptable salt or solvate thereof.

3. The compound according to Claim 1 wherein, the compound of formula I is:



15

or a pharmaceutically acceptable salt or solvate thereof.

4. The compound according to any one of the preceding claims, wherein the pharmaceutically acceptable salt is an alkali metal salt, an alkaline earth metal salt or a quaternary ammonium salt of the compound of formula I.

20

5. The compound according to Claim 4 wherein the pharmaceutically acceptable salt is a sodium or potassium salt of the compound of formula I.

6. A pharmaceutical formulation comprising a compound as defined in any one of Claims 1 to 5, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

5 7. The pharmaceutical formulation according to Claim 6, wherein the pharmaceutically acceptable excipient is a basic excipient.

8. The pharmaceutical formulation according to Claim 6 or Claim 7, wherein the pharmaceutically acceptable excipient is selected from the group consisting of
10 magnesium oxide, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, magnesium carbonate and calcium carbonate.

9. The pharmaceutical formulation according to any one of Claims 6 to 8, wherein
15 the formulation further comprises an enteric coating.

10. A compound of formula I as defined in any one of Claims 1 to 5, or a pharmaceutically acceptable salt thereof, or a pharmaceutical formulation as defined in any one of Claims 6 to 9 for use in medicine.

20 11. A compound of formula I as defined in any one of Claims 1 to 5, or a pharmaceutically acceptable salt thereof, or a pharmaceutical formulation as defined in any one of Claims 6 to 9 for use in the treatment of a disorder or condition ameliorated by the activation of AMPK.

25 12. Use of a compound of formula I as defined in any one of Claims 1 to 5, or a pharmaceutically acceptable salt thereof, or a formulation as defined in any one of Claims 6 to 9 in the manufacture of a medicament for the treatment of a disorder or condition ameliorated by the activation of AMPK.

30 13. A method of treating a disorder or condition ameliorated by the activation of AMPK comprising administering a compound of formula I as defined in any one of Claims 1 to 5, or a pharmaceutically acceptable salt thereof, or a formulation as defined in any one of Claims 6 to 9, to a subject in need thereof.

35 14. The compound for use according to Claim 11, the use according to Claim 12 or the method according to Claim 13, wherein the disorder or condition ameliorated by the activation of AMPK is selected from the group consisting of cardiovascular disease

(such as heart failure), diabetic kidney disease, type 2 diabetes, insulin resistance, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, pain, opioid addiction, obesity, cancer, inflammation (including chronic inflammatory diseases), autoimmune diseases, osteoporosis and intestinal diseases.

5

15. The compound for use according to Claim 11, the use according to Claim 12 or the method according to Claim 13, wherein the disorder or condition ameliorated by the activation of AMPK is a condition associated with hyperinsulinemia selected from the group consisting of obesity and cardiovascular disease.


10

16. The compound for use, use or method according to any one of Claims 11 to 15, wherein the compound is administered orally, subcutaneously or intramuscularly.

15

17. A process for preparing a compound as defined in any one of Claims 1 to 5, which process comprises:


(i) reaction of a compound of formula V,



20

with a suitable acid or acid anhydride; or

(ii) reaction of a compound of formula VI,



25

with a suitable acid or suitable acid salt.




Figure 1




Figure 2

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2021/052535

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D285/08 C07F9/09 A61P3/10 A61K31/433
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D C07F A61P A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2011/004162 A2 (BETAGENON AB [SE]; WESTMAN JACOB [SE] ET AL.) 13 January 2011 (2011-01-13) cited in the application abstract page 58; compound 4j claim 1 -----	1-17
A	WO 2013/108026 A1 (BALTIC BIO AB [SE]) 25 July 2013 (2013-07-25) abstract claim 1 -----	1-17
A	WO 2020/095010 A1 (BALTICGRUPPEN BIO AB [SE]) 14 May 2020 (2020-05-14) abstract claim 1 -----	1-17

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

13 January 2022

Date of mailing of the international search report

24/01/2022

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Bissmire, Stewart

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2021/052535

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2011004162 A2	13-01-2011	AU 2010270030 A1	12-01-2012
		BR 112012000370 A2	22-11-2016
		CA 2767291 A1	13-01-2011
		CN 102596923 A	18-07-2012
		DK 2451794 T3	14-03-2016
		EA 201200102 A1	30-08-2012
		EP 2451794 A2	16-05-2012
		ES 2567753 T3	26-04-2016
		HK 1170485 A1	01-03-2013
		HR P20160353 T1	06-05-2016
		HU E027263 T2	28-10-2016
		IL 216723 A	28-09-2017
		JP 5982281 B2	31-08-2016
		JP 2012532854 A	20-12-2012
		KR 20120054568 A	30-05-2012
		ME 02443 B	20-09-2016
		MX 337516 B	09-03-2016
		NZ 597075 A	28-03-2013
		PL 2451794 T3	29-07-2016
		SG 177558 A1	28-02-2012
		SM T201600225 B	31-08-2016
		US 2012183537 A1	19-07-2012
		US 2016128993 A1	12-05-2016
		WO 2011004162 A2	13-01-2011
		ZA 201108901 B	30-08-2017

WO 2013108026 A1	25-07-2013	NONE	

WO 2020095010 A1	14-05-2020	AU 2018448511 A1	27-05-2021
		CA 3118629 A1	14-05-2020
		WO 2020095010 A1	14-05-2020
